Search 

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in 1996. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.

Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better

Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.

Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.

Pregene is a world-leading cell and gene therapy company. Pregene is committed to develop innovative gene and cell therapy technologies and create reliable products from continued innovation and R&D. And pregene can provide CDMO service.

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.

Strategikon Pharma is the developer of Clinical Maestro™, which is an end-to-end elegant cloud-based platform to more efficiently budget, source and manage complex clinical programs. We believe that intuitive technology, complete transparency and effective communication between biopharmaceutical companies and providers will revolutionize the productivity of clinical research.

Clinical Maestro™: Modernize the outsourcing

SynCore Biotechnology Co., Ltd ("SynCore" 4192:TT) is a new drug and medical devices development company that integrates innovative technological platforms with current unmet medical needs. SynCore has a comprehensive pipeline in the therapeutic areas of oncology, ophthalmology, dermatology and infectious diseases, with experienced R&D, regulatory, manufacturing and commercialization teams.

Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.